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Lung cancer has been the most common can-
cer in the world for many years now. According 
to the estimations of the International Agency for 
Research on Cancer there were more than 1,8 mil-
lion new cases of lung cancer in 2012 worldwide. 
This was equivalent to 12,9% of all new cancer 
episodes. Importantly, the Central and Eastern 
Europe was the most endangered region charac-
terized by the highest estimated age-standardized 
incidence of lung cancer in men in the world 
(53.5 per 100 000). Although the incidence rate 
in women was considerable lower (10.4 per 100 
000) even in comparison to other parts of Europe, 
Northern (23.7 per 100 000) or Western (20.0 per 
100 000), the trend has been consistently and 
alarmingly growing in recent years [1]. Likewise, 
the mortality data closely mirrored the incidence 
rates in men and women, with 47.6 and 8.3 per 
100 000 respectively. Unfortunately, Polish data 
have been very consistent with this pattern and 
unfailingly one of the highest in Europe with 
overall incidence of 38 per 100 000 and mortal-
ity of 33.4 per 100 000. Within the last decade 
(2002−2012) the standardized incidence rate in 
men dropped by 20% and increased by as much as 
25.4% in women [2]. Accordingly, mortality rates 
in men fell by 22% and raised by 19% in women. 
Not surprisingly those alarming data reflect well 
the current trends in cigarette smoking in Poland. 
In the current issue Grądalska-Lampart et al. 
publish very interesting in-depth analysis of the 
lung cancer epidemiology in the south eastern 
Podkarpacie region of Poland between 2002 and 
2012 [3]. While statistics for this province have 
been considered for years as one of the most 
favourable in the country, the authors clearly 
showed that the overall national trends were mir-
rored quite exactly. Within the decade, the overall 
number of lung cancer cases in men dropped by 
22.4% and increased by 22.5% in women. This 
was followed by similar shift in deaths; −16.6% 
and +21.5%, respectively. Not surprisingly, the 
estimated risks for lung cancer diagnosis and 
lung cancer related death was the highest for the 
age group 65+. Yet, the considerable shift by as 
much as two decades in the incidence peak for 
women demonstrated in this paper, from 80−84 
age group in 2002 down to 60−64 in 2012 should 
be considered alarming. Also, authors very con-
sistently demonstrated the striking differences 
regarding both the incidence and mortality within 
the region. Surprisingly, there were no clear cut 
differences in incidence between rural and urban 
counties (poviat bieszczadzki vs Rzeszów: 27.3 
vs 24.1 per 100 000) as well as rural and indus-
trialized counties (bieszczadzki vs stalowowolski 
27.3 vs 20.7 per 100 000). More importantly, there 
were considerable variations between urban areas 
within the region not only in terms of incidence 
but more importantly mortality (Tarnobrzeg vs. 
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Rzeszów vs Przemyśl: 19.3 vs 20.4 vs 29.0 per 
100 000). In this regard, Przemyśl claimed the 
top position for both incidence and mortality due 
to lung cancer in south eastern Poland between 
2002−2012, 35.2 and 29.0 per 100 000 respec-
tively. Unfortunately, while this paper provides 
solid epidemiological data, it is not, and rightfully 
so, the structural systematic analysis thoroughly 
investigating the socio-economic issues as well 
as the healthcare organization details that might 
have contributed to those somewhat surprising 
and definitely alarming data. 
Meanwhile, it should be clearly stated that 
the overall survival rates for lung cancer did not 
improved significantly anywhere in the world. 
The latest data claim 5-years survival rate at 
16,8% for UK (years 2004−2010), 15.61% for Ger-
many and 14.25% for Poland (years 2000−2007) 
[4, 5]. The tremendous efforts have been made 
in recent years to increase early identification 
of lung cancer patients as well as to improve 
the effectiveness of currently applied and novel 
therapeutic algorithms. The early diagnostic pro-
grams employing the low-dose CT screening have 
been introduced in many countries including 
Poland [6, 7]. While, the feasibility of screening 
programs directed at high-risk groups have been 
demonstrated, the strategy is still challenged by 
number of problems like high false positive rates 
or over-diagnosis of indolent disease [7, 8]. Re-
cently published results of the European NELSON 
trial presented the new very promising approach 
using the three-dimensional assessment of the 
lung nodule for the CT screening [9]. However, 
the same authors clearly emphasized the urgent 
need to define and standardize the key screening 
parameters [10]. 
In parallel, many attempts have been made 
in the past decade to translate the latest achieve-
ments of molecular biology into the clinical 
practice. Although very promising none of the 
molecular signatures, free circulating DNA or 
circulating cancer cells have been as yet approved 
as the early diagnostic or prognostic biomarker 
for the clinical use [11, 12]. 
Quite opposite, the molecular diagnostics 
has been very rapidly evolving as the useful and 
reliable tool for the assessment of predictive bio-
markers in oncology. At the moment, it provides 
information indispensable for the decision-mak-
ing process on the optimal therapeutic approach 
in non-small lung cancer patients. The tissue 
evaluation in search for the EGFR gene mutations, 
ALK and ROS-1 gene rearrangements is currently 
considered the requisite part of diagnostic algo-
Table 1. Diagnostic algorithm for non-small lung cancer 
diagnostic samples as suggested by the current 
guidelines [15]
PULMONOLOGIST/ONCOLOGIST  
Diagnostic sample simultaneously referred to the morphological  
and molecular evaluation*
PATOLOGIST: 
Diagnosis  of non-small cell lung cancer characterized by the   
non-squamous cell or NOS (not otherwise specified) morphology 
Estimation of cancer cells relative number (%) in the sample  
reffered to molecular analysis
within 3 working days**
MOLECULAR BIOLOGIST: 
EGFR gene exons 18−21 assessment for the  activating/ 
/resistance mutations. If negative evaluation for ALK gene rear-
rangement 
within 3–5 working days (no longer than 10)
*Futher molecular diagnostic for pathologist’s discretion conditional on tumor 
morphology
**To  prepare material for molecular analyses
rithm recommended by international and Polish 
guidelines [13, 14]. The Polish position paper 
published in 2014 very clearly states the need 
to include the molecular testing into the routine 
clinical practice [14]. The methodological rec-
ommendations announced soon after, provide 
Polish medical community with the complete 
information regarding the diagnostic process, i.e. 
material handling, essential molecular methods 
as well as the key technical and legal require-
ments for the laboratory performing the diagnos-
tics [15]. Importantly, the guidelines describe the 
suggested diagnostic algorithm specifying in de-
tail the recommended time-frame for respective 
steps as outlined in Table 1. In the current times 
of austerity for Polish healthcare system, the 
algorithm and in particular the time constraints 
might seem unrealistic. However, our daily prac-
tice at the National Institute of Tuberculosis and 
Lung Diseases in Warsaw keeps on proving that 
its implementation although difficult is quite 
feasible, as long as all involved parties: doctors, 
pathologists and molecular biologists are keen 
to cooperate. Modern standards of diagnostics 
and therapy necessitate the reliable and efficient 
decision-making process, ideally providing lung 
cancer patients with the earliest possible diag-
nosis and the optimal treatment. It would not 
be possible to improve the current statistics for 
the 5 years survival rate of lung cancer patients 
without determination to implement new and 
sometimes difficult protocols into the clinical 
routine. 
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